GlassScriptPhysician profile
Fnu Pranav
NPI 1952327116
$2,515.82
in general payments reported to CMS, 2019-2025
22 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $144 · 2021: $305 · 2022: $379 · 2023: $592 · 2024: $261 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,162.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,070.17 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $284.41 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.71 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Abbott Laboratories | $140.62 | 2022-2025 | Eterna, Freestyle Libre 3, Cardiomems |
| Boston Scientific Corporation | $91.92 | 2021 | |
| Abiomed | $86.88 | 2019-2025 | |
| Daiichi Sankyo INC. | $85.58 | 2023 | Injectafer |
| Intuitive Surgical, INC. | $79.99 | 2025 | |
| Pfizer INC. | $75.70 | 2024 | |
| Corcept Therapeutics | $64.24 | 2019-2025 | Korlym |
| Lilly USA, LLC | $52.31 | 2022-2024 | Mounjaro, Zepbound, Trulicity |
| Novartis Pharmaceuticals Corporation | $46.51 | 2022-2024 | |
| Glaxosmithkline, LLC. | $39.37 | 2022-2023 | Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $37.85 | 2023 | |
| Shire North American Group INC | $34.02 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33.32 | 2022-2023 | Verquvo |
| Novo Nordisk INC | $31.25 | 2019-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $24.88 | 2019 | |
| Amgen INC. | $24.81 | 2019-2023 | Repatha |
| Lexicon Pharmaceuticals, INC. | $21.85 | 2023 | Inpefa |
| Exact Sciences Corporation | $20.69 | 2025 | The Cologuard Plus Collection Kit |
| Kiniksa Pharmaceuticals International, Plc | $15.74 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fnu Pranav listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.